Chancellor hints at more money for health service
Will the Chancellor follow through on his hint of financial boost for NHS? Chancellor Philip Hammond has offered conditional promise of more money for…
Pharma leaders have warned of possible medicines shortages and public health crises if Brexit negotiators fail to get legal and regulatory changes right in the next round of talks.
A joint report from the Association of the British Pharmaceutical Industry (ABPI) and the BioIndustry Association (BIA) says that in the event of Europe and the UK no longer co-operating as they do now on medicines and public health, key findings (produced by OHE Consulting) show:
The report came out shortly after the Prime Minister Theresa May returned from Brussels having concluded phase one of Brexit negotiations, in which rights of EU citizens living and working in the UK were agreed.
BIA chief executive Steve Bates this week appeared before the House of Commons Health Select Committee.
‘The complex issues surrounding medicines regulation and supply chain need to be front and centre in the second phase of talks,’ he told the Committee’s MPs.
‘And industry needs a realistic transition period to ensure that the supply of lifesaving and life extending medicines to patients in the UK and across Europe is not affected.